Meeting Details - The sixth board meeting of Guizhou Bailing Pharmaceutical Group Co., Ltd. was convened by Chairman Jiang Wei on June 18, 2025 [2][3] - The meeting was held at the company's conference room with all 9 board members present, including independent directors participating via communication [3][4] Resolutions Passed - The board approved the proposal to apply for the removal of other risk warnings, with a unanimous vote of 9 in favor [6][9] - The board also approved a proposal for the company to provide a guarantee for its subsidiary, Anshun Dajiankang Pharmaceutical Industry Operation Co., Ltd., for a loan of 148 million yuan, with the company guaranteeing 81.4 million yuan [7][9] - A proposal to convene the second extraordinary general meeting of shareholders in 2025 was also approved unanimously [10][11] Guarantee Details - The subsidiary intends to apply for a loan of 148 million yuan from Guizhou Bank for a term of 2 years, with the company providing a guarantee based on its 55% ownership [15][21] - The total amount of guarantees provided by the company and its subsidiaries will reach 213.4 million yuan, accounting for 6.71% of the company's latest audited net assets [23] Risk Warning Removal - The company was previously under risk warning due to a negative internal control audit report for 2023, which has since been rectified [25][26] - The company has implemented various measures to improve internal controls and has received a qualified audit report for 2024, indicating compliance with the requirements for removing the risk warning [28][29] Upcoming Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for July 4, 2025, with provisions for both on-site and online voting [31][32] - Shareholders must register by June 27, 2025, to participate in the meeting [35]

证券代码：002424 证券简称：ST百灵 公告编号：2025-028 贵州百灵企业集团制药股份有限公司 关于申请撤销其他风险警示的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 特别提示：关于贵州百灵企业集团制药股份有限公司（以下简称"公司"） 申请撤销对公司股票交易实施其他风险警示事项尚需深圳证券交易所批准同意， 存在不确定性，敬请广大投资者注意投资风险。 2024年度公司围绕"摘帽扭亏"核心任务，全体员工在董事会的 领导下，全力开展内控整改及质量专项提升工作，采取以下整改和提 升措施： （1）根据最新的法律法规及规范运作规则，结合《企业内部控 制基本规范》及配套指引的有关要求，公司全面梳理、完善内部制度； （2）在审计委员会的监督和指导下，加强内部审计部门的审计 监督职能。公司内部审计部门、财务部门和市场监管部门密切关注、 定期核查公司与经销商之间销售费用政策执行、费用结算、费用计提、 款项回收等方面工作，修订完善销售费用政策，规范市场费用票据报 销管理，完善年度销售费用统计确认等，明确职责并建立奖惩机制， 确保各部门严格执行流程，提升公司规范化 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2025-029 贵州百灵企业集团制药股份有限公司 关于对控股子公司提供担保的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 特别提示： 本公司对安顺市大健康医药产业运营有限公司（资产负债率 85.79%）的担保金额为 10,890 万元,占公司最近一期经审计净资产的 比例为 3.42%。请投资者充分关注担保风险。 一、担保事项概述 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）控 股子公司安顺市大健康医药产业运营有限公司（以下简称"大健康医 药"）原向贵州银行股份有限公司安顺分行申请的贷款 14,800 万元即 将到期，为保障其资金正常运转，大健康医药拟向贵州银行股份有限 公司安顺分行申请续贷款 14,800 万元，期限为 2 年，公司将继续按 持股比例 55%提供连带责任担保 8,140 万元，大健康医药另一股东安 顺市医投科技服务有限公司将按持股比例 45%提供连带责任担保 6,660 万元。 2、董事会审议情况 申请贷款提供担保的议案》，本议案需提交股东大会审议。 3、根据《深圳 ...

证券代码：002424 证券简称：ST百灵 公告编号：2025-030 贵州百灵企业集团制药股份有限公司 关于召开 2025 年第二次临时股东会通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）将于2025年7月4 日召开2025年第二次临时股东会，现将本次会议的有关事项通知如下： 一、召开会议的基本情况： （一）股东会届次：2025年第二次临时股东会 （二）股东会召集人：本次股东会由董事会召集，《关于召开2025年第二次 临时股东会的议案》已经公司第六届董事会第十七次会议审议通过。 （三）会议召开的合法、合规性：本次股东会的召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》等的规定。 （四）现场会议召开的日期、时间及网络投票时间： 1、现场会议召开的日期、时间：2025年7月4日（星期五）上午十时 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为2025年7月4日（现场股东会召开当日）的交易时间，即9:15—9:25,9:30—11:30 和13:00—15: ...

证券代码：002424 证券简称：ST百灵 公告编号：2025-027 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十七次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 2、本次董事会于2025年6月18日上午10:00在公司三楼会议室以 现场结合通讯方式召开。 3、本次董事会应参会表决董事共9人，实际参会表决的董事9人。 其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持，公司监事和高级管理人 员列席了本次董事会。 5、本次董事会的召集、召开符合《公司法》《公司章程》《董事 会议事规则》及相关法规的规定。 二、会议审议情况 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《关于申请撤销其他风险警示的议案》； 具 体 内 容 详 见 公 司 在 指 定 信 息 披 露 媒 体 巨 潮 资 讯 网 （www.cninfo.com.cn）、《证券时报》《证券日报》《中国证券报》 《上海证券报》披露的《关于申请撤销其他风险警示的公告》。 一、会议召开情况 1、贵州百灵企业集团制药股 ...

Summary of Key Points Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. plans to provide a guarantee for its subsidiary, Anshun Dajiankang Pharmaceutical Industry Operation Co., Ltd., to secure a loan of 148 million yuan from Guizhou Bank for a period of 2 years, reflecting the company's support for its subsidiary's operational needs and long-term business development [1][4]. Group 1: Guarantee Details - The subsidiary, Anshun Dajiankang, is applying for a loan of 148 million yuan, with the company providing a guarantee of 81.4 million yuan based on its 55% ownership stake [1][4]. - The other shareholder, Anshun Medical Investment Technology Service Co., Ltd., will provide a guarantee of 66.6 million yuan based on its 45% ownership stake [4]. - The board of directors has approved the guarantee, which will be submitted for shareholder meeting review [1][2]. Group 2: Financial Position - After this guarantee, the total amount of external guarantees provided by the company and its subsidiaries will be 213.4 million yuan, which is 6.71% of the company's most recent audited net assets [4]. - The guarantees provided to external entities outside the consolidated statements amount to 24.5 million yuan, representing 0.77% of the company's most recent audited net assets [4]. - The guarantees to the subsidiary total 188.9 million yuan, accounting for 5.94% of the company's most recent audited net assets [4]. Group 3: Company and Subsidiary Information - Anshun Dajiankang was established on May 30, 2003, with a registered capital of 10 million yuan and operates in various pharmaceutical and health-related sectors [2]. - The company has a good operational and credit status, indicating its capability to repay the loan [4].

Meeting Overview - The sixth board of directors held its 17th meeting, convened by Chairman Jiang Wei, combining on-site and communication methods for voting [1] - Independent directors participated via communication methods [1] Resolutions Passed - The board approved the proposal to apply for the removal of other risk warnings, with a unanimous vote of 9 in favor [1] - The board approved a proposal for the company to provide guarantees for its subsidiary, Anshun Dajiankang Pharmaceutical Industry Operation Co., Ltd., which is applying for a loan of 148 million yuan from Guizhou Bank for a term of 2 years. The company will provide a guarantee of 81.4 million yuan, while another shareholder will provide a guarantee of 66.6 million yuan [1] - The board approved the proposal to convene the second extraordinary general meeting of shareholders in 2025, with a unanimous vote of 9 in favor [2]

证券代码：002424 证券简称：ST 百灵 公告编号：2025-026 贵州百灵企业集团制药股份有限公司 关于 2024 年度股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2025年5月19日（星期一）上午十时 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为 2025 年 5 月 19 日（现场股东大会召开当日）的交易时间， 即 9:15—9:25,9:30—11:30 和 13:00—15:00。通过深圳证券交易所 互联网投票系统进行网络投票的开始时间为 2025 年 5 月 19 日（现场 股东大会召开当日）9:15，结束时间为 2025 年 5 月 19 日（现场股东 大会结束当日）15:00。 3、召开方式：现场投票和网络投票相结合的方式 4、会议召集人：公司董事会 5、会议主持人：董事长姜伟先生 6、本次股东大会的召集和召开符 ...

贵州北斗星律师事务所 BEIDOUXING LAW OFFICE 贵州省贵阳市观山湖区金朱东路 399 号贵阳恒大中心 B 座 24 楼 邮编:550001 电话:86901517 传真:86901634 电子邮箱:10263336540qq.com 关于贵州百灵企业集团制药股份有限公司 2024 年度股东大会的 法律意见书 [2025] 黔北律法意见字第 168 号 致. 贵州百灵企业集团制药股份有限公司 贵州北斗星律师事务所(以下简称"本所")接受贵州百灵企业集 团制药股份有限公司(以下简称"公司")委托,指派本所律师文廷 杰、张妮出席了公司于 2025年5月19日上午 10:00 在贵州省安顺 市经济技术开发区西航路 212 号贵州百灵企业集团制药股份有限公 司会议室召开的公司 2024年度股东大会（以下简称"本次股东大 会"）。现根据《中华人民共和国公司法》、《中华人民共和国证券 法》等有关法律、法规及规章和《贵州百灵企业集团制药股份有限公 司章程》（以下简称〈"公司章程"）、《贵州百灵企业集团制药股 份有限公司股东大会议事规则》(以下简称"议事规则")的规定, 出具本法律意见书。 本所律师仅就本次股 ...

Group 1: Company Performance and Financials - In Q1 2025, the company experienced a significant decline in revenue due to high growth in the same period last year, insufficient market demand, and strategic adjustments [2] - For the year 2024, the company achieved a revenue of CNY 3.825 billion and a net profit of CNY 33.62 million, successfully turning a profit [9][11] - The company aims to enhance its core capabilities and adapt to market changes by leveraging smart technologies and data analytics [15] Group 2: Product Development and Market Strategy - The company is focusing on its core business and exploring new economic growth points while enhancing existing product potential [2][15] - The "Huanglian Jiedu Wan" product has completed Phase III clinical trials with 840 cases, aiming to provide new treatment options for various diseases [4] - The company plans to deepen its marketing reforms and expand its coverage across provinces [2][4] Group 3: Corporate Governance and Compliance - The company is under investigation by the China Securities Regulatory Commission (CSRC) for alleged information disclosure violations, which has led to a risk warning on its stock [9][11] - The company has established a special task force to improve internal controls and rectify issues identified in the audit report [11][14] - The chairman reassured investors about the company's future, emphasizing ongoing reforms and compliance efforts [5][8] Group 4: Shareholder Relations and Future Plans - As of May 9, 2025, the total number of shareholders was 77,269, showing a slight decrease from 77,352 on April 30, 2025 [14] - The company has conducted a share buyback, effectively treating it as a cash dividend, and plans to continue focusing on shareholder returns [16] - Future plans include maintaining communication with regulatory bodies to lift the risk warning status and improve corporate governance [14]